These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 20068179)

  • 21. V599EB-RAF is an oncogene in melanocytes.
    Wellbrock C; Ogilvie L; Hedley D; Karasarides M; Martin J; Niculescu-Duvaz D; Springer CJ; Marais R
    Cancer Res; 2004 Apr; 64(7):2338-42. PubMed ID: 15059882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
    Park S; Yeung ML; Beach S; Shields JM; Yeung KC
    Oncogene; 2005 May; 24(21):3535-40. PubMed ID: 15782137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
    Becker TM; Boyd SC; Mijatov B; Gowrishankar K; Snoyman S; Pupo GM; Scolyer RA; Mann GJ; Kefford RF; Zhang XD; Rizos H
    Oncogene; 2014 Feb; 33(9):1158-66. PubMed ID: 23455323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-RAF: A contributor to the melanoma phenotype.
    Heath EM; Kaufman KL; Christopherson RI
    Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS; Ghoreschi K; Sander CA; Röcken M
    Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
    Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
    Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma.
    Liao YH; Hsu SM; Huang PH
    Cancer Res; 2007 Dec; 67(24):11547-56. PubMed ID: 18089783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
    Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
    Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
    J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.
    Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A
    BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring oncogenic B-RAF-induced senescence in melanocytes.
    Tran SL; Rizos H
    Methods Mol Biol; 2013; 965():313-26. PubMed ID: 23296668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas.
    Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L
    Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
    Christensen C; Guldberg P
    Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.
    Denoyelle C; Abou-Rjaily G; Bezrookove V; Verhaegen M; Johnson TM; Fullen DR; Pointer JN; Gruber SB; Su LD; Nikiforov MA; Kaufman RJ; Bastian BC; Soengas MS
    Nat Cell Biol; 2006 Oct; 8(10):1053-63. PubMed ID: 16964246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.